| 영문 | luteinizing hormone(LH) | 한글 | 황체형성호르몬 |
|---|---|---|---|
| 설명 | 여성의 월경은 정해진 순서에 의해 일어나게 된다. 먼저 난포자극호르몬이 뇌에서 분비되어 여성의 난소를 자극하게 되면 난포가 자극받아 난포호르몬(에스트로젠)을 분비하게 되고 이것은 다시 되먹이기 메커니즘 의해 뇌에 작용을 하여 황체화호르몬이 뇌에서 분비되고 이것이 이른바 절정에 이르렀을 때, 난포에서 배란이 일어나게 된다. 이후 난포는 황체로 변하게 되며, 배란된 난자가 수정되지 아니하면, 황체는 황체호르몬(프로게스테론)을 분비한 뒤 퇴화되고 곧 이어 월경이 일어나게 된다. 이 일은 정상적인 대부분의 여성에서 28일을 주기로 일어나며, 대개 황체화호르몬 절정 이후 마지막은 14일로 일정하다고 한다. |
||
| GRH | Growth hormone Releasing Hormone |
|---|---|
| FRH | follicle-stimulating hormone-releasing hormone |
| FSH-RH | follicle-stimulating hormone-releasing hormone |
| GDH | glucose dehydrogenase; glutamate dehydrogenase; glycerophosphate dehydrogenase; glycol dehydrogenase... |
| GH-RH | growth hormone-releasing hormone |
| muscarinic antagonists | Drugs that bind to but do not activate muscarinic cholinergic receptors (receptors, muscarinic), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development. (12 Dec 1998) |
|---|---|
| heparin antagonists | Coagulant substances inhibiting the anticoagulant action of heparin. (12 Dec 1998) |
| prostaglandin antagonists | Compounds that inhibit the action of prostaglandins. (12 Dec 1998) |
| histamine antagonists | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonist. Classical antihistaminics block the histamine h1 receptors only. (12 Dec 1998) |
| histamine h1 antagonists | Drugs that selectively bind to but do not activate histamine h1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonise or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system h1 receptors are not as well understood. (12 Dec 1998) |
| histamine h2 antagonists | Drugs that selectively bind to but do not activate histamine h2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (12 Dec 1998) |
| serotonin antagonists | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin agonists. (12 Dec 1998) |
| narcotic antagonists | Agents inhibiting the effect of narcotics on the central nervous system. (12 Dec 1998) |
| nicotinic antagonists | Drugs that bind to nicotinic cholinergic receptors (receptors, nicotinic) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (12 Dec 1998) |
| dopamine antagonists | Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of tourette syndrome, and for hiccup. (12 Dec 1998) |
| opioid antagonists | Agents such as naloxone and naltrexone which have high affinity for opiate receptors but do not activate these receptors. These drugs block the effects of exogenously administered opioids such as morphine, heroin, meperidine, and methadone, or of endogenously released endorphins and enkephalins. (05 Mar 2000) |
| estradiol antagonists | Compounds which inhibit or antagonise the biosynthesis or action of estradiol. (12 Dec 1998) |
| excitatory amino acid antagonists | Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (12 Dec 1998) |
| folic acid antagonists | Inhibitors of the enzyme, dihydrofolate reductase (tetrahydrofolate dehydrogenase), which converts dihydrofolate (fh2) to tetrahydrofolate (fh4). They are frequently used in cancer chemotherapy. (12 Dec 1998) |
| 5-hydroxy tryptamine antagonists | Agents which block serotonin receptors and hence interfere with the biological actions of serotonin (5-HT). (05 Mar 2000) |